47 results about "Proteus mirabilis" patented technology

The invention discloses a urinary system infection pathogen and drug resistance gene detection system and a kit. The detection system comprises forward and reverse primers which are respectively used for detecting escherichia coli, staphylococcus aureus, acinetobacter baumannii, klebsiella pneumoniae, enterococcus faecium, candida glabrata, proteus mirabilis, enterococcus faecalis, candida tropicalis, enterobacter cloacae, candida albicans, pseudomonas aeruginosa and streptococcus agalactiae; the forward primer and the reverse primer are respectively used for detecting the blaCTX-M gene of the extended spectrum beta-lactamase, the forward primer and the reverse primer are used for detecting the blaSHV gene of the extended spectrum beta-lactamase, and the forward primer and the reverse primer are used for detecting the blaTEM gene of the extended spectrum beta-lactamase. According to the forward and reverse primers for detecting the blaNDM gene of the extended-spectrum beta-lactamase, a detection sample is urine. According to the invention, common gram-negative bacteria, gram-positive bacteria and fungi can be detected at the same time, and the problem of missed detection of mixed infection in traditional culture is solved.

The invention relates to a bacteriophage, in particular to a cross-host multivalent bacteriophage and preparation and application of a bacteriostatic agent of the bacteriophage, the multivalent bacteriophage is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2026045. The salmonella bacteriophage CCTCC NO: M 2026045 is found for the first time, is a multivalent bacteriophage, can cross-host infect and split multiple important livestock and poultry intestinal pathogens such as salmonella, escherichia coli, shigella, klebsiella pneumoniae and proteus mirabilis, solves the problem of narrow host range of a single bacteriophage, and improves the prevention and control efficiency. By inhibiting the overgrowth of the gram-negative pathogenic bacteria, the intestinal microecological balance can be regulated, so that the aim of effective prevention and control is fulfilled.

The present application relates to the field of pharmaceutical chemistry, and specifically discloses a emodin mannich base, a preparation method and application thereof. The emodin mannich base has a structure as shown in formula I, the structure is simple, has strong in-vitro antimicrobial activity, especially high inhibitory activity to staphylococcus aureus, bacillus subtilis, micrococcus luteus, escherichia coli, proteus vulgaris, pseudomonas aeruginosa, shigella dysenteriae, salmonella typhimurium and other bacteria, and candida utilis, candida albicans, saccharomyces cerevisiae, monascus and other fungi, and can be used for preparing antibacterial and / or antifungal drugs.

The present invention discloses a meso-diaminopimelate dehydrogenase mutant of Proteus vulgaris and its application, belonging to the technical field of bioengineering. The present invention constructs a PvDAPDH mutant, which, compared with the wild enzyme, can catalyze the synthesis of D-amino acids from a variety of aromatic α-ketoacids, and the stereoselectivity can reach 95%. The triple mutant W121I / H227I / R181S of pvDAPDH constructed in the present invention shows good compatibility with different large-volume aromatic α-ketoacid substrates, can simultaneously catalyze the conversion of most aromatic α-ketoacid substrates into D-amino acids, shows high catalytic activity towards 2-oxo-4-phenylbutyric acid, and the yield of the product D-homophenylalanine reaches 2.1 g / L. The present invention effectively expands the toolbox for the biosynthesis of aromatic D-amino acids.

The invention described herein pertains to a novel biological healing agent specifically formulated for use in mortar, aiming to enhance the longevity and durability of construction materials. Tradicional mortar and concrete structures are susceptible to cracking and degradation over time. This inventions seeks to address these problems by integrating a bacterial-based solution comprising Proteus mirabilis and an organic calcium source that promotes self-healing when cracks occur.

The invention provides application of bacillus subtilis JY166 in preparation of a microecological preparation or feed for soft-shelled turtles, and belongs to the technical field of aquatic animal breeding. The bacillus subtilis JY166 is separated from intestinal tracts of soft-shelled turtles, is identified to have the following characteristics that the bacillus subtilis JY166 is gram-positive, is rod-shaped, has spores, can grow in the environment with the temperature of 15-40 DEG C, the pH value of 6-11 and the NaCl concentration of less than or equal to 3wt%, and has a remarkable antagonistic effect on common proteusbacillus vulgaris, serratia marcescens and proteusbacillus penneri which are common in soft-shelled turtle culture. The invention further provides a soft-shelled turtle microecological preparation and feed containing the strain, double inhibition of pathogenic bacteria in soft-shelled turtle intestinal tracts and aquaculture water can be achieved through water application or feed addition, the micro-ecological environment is improved, disease occurrence is reduced, the requirement for green development of fishery is met, and good application prospects are achieved.

The invention belongs to the technical field of microorganisms, and particularly relates to a novel strain of brevibacterium and application thereof. The strain is separated from rapana venosa, is a new species of Brevibacterium, is named as Brevibacterium sp. M-17, is registered and preserved in the China Center for Type Culture Collection (CCTCC), and has the preservation number of CCTCC NO: M 20241860. The Brevibacterium sp. M-17 strain disclosed by the invention has obvious bacteriostatic activity on bacillus subtilis, escherichia coli, shewanella, enterobacter aerogenes, staphylococcus aureus and proteus vulgaris, has obvious antioxidant activity, has alpha-glucosidase inhibitory activity, can generate gelatinase, cellulase and amylase, and can be used for preparing an anti-inflammatory agent. The strain can be applied to preparation of bacteriostatic agents, antioxidants, alpha-glucosidase inhibitors, gelatinase, cellulase and amylase, can also be applied to industrial production instead of the bacteriostatic agents, the antioxidants, the gelatinase, the cellulase and the amylase in a viable bacterium form, and has good development and application prospects.

The application discloses a cadmium-resistant proteus mirabilis and application thereof in treatment of composite pollution environment. Priestia megaterium The application provides a PBAT-degrading bacterium, i.e., a proteus mirabilis (S261-3) strain, which can grow at a temperature of 10-50 DEG C and has certain salt and cadmium resistance, and can grow normally in a high-salt or high-cadmium concentration range. Meanwhile, the S261-3 strain has a good PBAT-degrading effect, and can degrade PBAT under cadmium stress, and can be used for degrading plastic pollutants in cadmium-polluted soil. The microbial strain provided by the application has stronger adaptability to a polluted environment, meets the repair demand of a composite pollution site, can be used for comprehensive treatment of microplastic and heavy metal composite pollution, is helpful to improving soil quality and improving land utilization efficiency, and has important practical significance for soil composite pollution repair.

The invention belongs to the technical field of microorganisms, and particularly discloses application of proteusbacillus vulgaris Ch8 to reduction of cadmium content of ligusticum wallichii and promotion of accumulation of medicinal components of ligusticum wallichii. The method comprises the following steps: a bacterial suspension of the Proteus sp. Ch8 is applied to rhizosphere soil of ligusticum wallichii, and cultivation and planting are carried out. According to the application, the proteusbacillus vulgaris Ch8 is applied to ligusticum wallichii planting, so that the cadmium content of medicinal parts can be remarkably reduced, and meanwhile, accumulation of medicinal components such as ferulic acid, ligustilide and senkyunolide I of ligusticum wallichii is promoted. The application is simple and convenient to operate, healthy and safe, the toxicity of cadmium can be effectively reduced, and the efficacy quality and economic value of ligusticum wallichii are improved.

The present invention relates to a method for treating Gram-negative bacteria that are resistant to colistin (MIC > 50 mg / mL), an antibacterial compound, excluding those of the genera Burkholderia, Proteus, and Serratia, comprising contacting the bacteria with an aqueous pharmaceutical composition containing a rose bengal (RB) compound of formula I, dissolved or dispersed at a concentration of about 0.01 to about 15 mg / mL, and irradiating the contacted bacteria with light of a wavelength of about 500 nm to about 600 nm for a period of about 1 to about 10 minutes, at a concentration of about 16 to about 160 J / cm². 2 The aim is to create a method that involves obtaining a certain amount of light to treat and kill irradiated bacteria. [Formula 1] JPEG2026511692000028.jpg5864 (where X, R 1 , R 2 (and M+ are defined herein)

The invention belongs to the technical field of bioengineering, and particularly relates to chondroitin sulfate ABC I lyase as well as a mutant and application thereof. The present invention provides a chondroitin sulfate ABC I lyase CSABC I-NS1, and a mutant CSABC I-NS1-muout of the enzyme, and a preparation method of the chondroitin sulfate ABC I lyase CSABC I-NS1-muout. The chondroitin sulfate ABC I lyase CSABC I-NS1 is derived from Proteus mirabilis, a mutant CSABCI-NS1-E502F with high enzyme activity and high stability is obtained after site-specific mutagenesis, the specific enzyme activity of the mutant CSABCI-NS1-E502F is 72.53 U / mg, and the half-life period of the mutant CSABCI-NS1-E502F at 37 DEG C is 96.80 h; and the method has important significance for realizing biological industrial preparation of low-molecular-weight chondroitin sulfate.

The present invention provides a lung squamous cell carcinoma patient immunotherapy effect prediction device, which comprises a detection unit and a data analysis unit, the detection unit extracts 9 types of intra-tumor bacteria as characteristic intra-tumor bacteria based on 16S rRNA sequencing data of a lung squamous cell carcinoma patient tumor puncture sample; the data analysis unit is used for constructing a data model for predicting the curative effect of immunotherapy on the basis of 16S rRNA sequencing data of tumor puncture samples of the characteristic intra-tumor bacteria and lung squamous cell carcinoma patients; the characteristic intra-tumorous bacteria comprise a plasmobacterium actinomycetes genus, an anaerobic bacillus genus, a kantobacterium genus, a Vinci bacterium genus, a kocuria genus, a freshwater bacterium genus, a microbacterium genus, an achromobacter genus and a proteus genus; the prediction device can predict whether immunotherapy of lung squamous cell carcinoma patients is effective or not, screening and hierarchical management can be conducted on the patients before treatment, and therefore individualized medication is guided, and the curative effect is improved.

The present invention discloses a membrane-bound L-amino acid deaminase mutant and its application. The membrane-bound L-amino acid deaminase mutant is obtained by mutating the wild-type PM1 enzyme derived from Proteus mirabilis. The amino acid sequence of the wild-type PM1 enzyme is shown in SEQ ID No. 1, and the mutation mode is any one of the following: (1) G259W; (2) D340N. The PM1 enzyme mutant of the present invention is obtained by mutating the wild-type PM1 enzyme derived from Proteus mirabilis. The turnover numbers of the whole cells of the two mutants G259W and D340N for catalyzing L-phenylalanine are increased by 1.3 times and 1.2 times respectively compared with that of the WT.

The invention discloses cadmium-resistant P.megaterium and an application of the cadmium-resistant P.megaterium in treatment of a combined polluted environment. The invention provides a PBAT (poly (butyleneadipate-co-terephthalate)) efficient degradation bacterium, namely, a Pristia megaterium S261-3 strain, and the strain can grow at the temperature of 10-50 DEG C, has certain salt and cadmium resistance, and can normally grow in a relatively high salt or cadmium concentration range. Meanwhile, the S261-3 strain has a good degradation effect on PBAT, can also degrade PBAT under cadmium stress, and can be used for degrading plastic pollutants in cadmium-polluted soil. The microbial strain provided by the invention has stronger adaptability to polluted environment, meets the repair requirement of a combined pollution site, can be used for comprehensive treatment of micro-plastic and heavy metal combined pollution, is beneficial to improvement of soil quality and improvement of land utilization efficiency, and has important practical significance for soil combined pollution repair.

The present invention relates to a vaccine composition for prophylactic use against Streptococcus pneumoniae infections. This composition contains inactivated bacteria of Escherichia coli, Morganella morganii, Proteus mirabilis, Klebsiella pneumoniae and Enterococcus faecalis and preferably dextran and an aluminum compound as adjuvant.

Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.

Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron-emitting mannitol analogue, [18F]fluoromannitol ([18F]FMtl), are rapidly taken up by gram-positive and gram-negative bacteria such as E. coli, S. aureus, A. baumannii, S. epidermis, P. mirabilis, S. enterica, K. pneumonia, E. faecium, E. cloacae, and M. marinum, but not non-active infection sites such as sterile inflammatory sites, cancer sites, etc. Administration of these radiopharmaceuticals to and subsequent imaging of patients, e.g., via positron emission tomography (PET), enables detection of deep-seated and difficult to manage bacterial infections, such as osteomyelitis and prosthetic joint infection, or in patients with sickle cell disease. [18F]FMtl injection detects and differentiates infection rapidly. The radiolabeled mannitol compounds can be produced via nucleophilic substitution reactions that are deployable on commercially available synthesizers, facilitating straightforward and wide accessibility, and counteracting unnecessary antibiotic use.

The application provides a preparation method of earthworm antibacterial crude protein and belongs to the technical field of biotechnology. The technical scheme comprises the following steps: stimulating earthworms with tea dregs liquid, homogenizing the earthworms, centrifugal separation, and obtaining earthworm antibacterial crude protein after freeze-drying. The earthworm species that can be used in the application include Octochaetus porrectus, Metaphire cummingi, Drawida japonica, Drawida hupehensis or Allolobophora clavata. The obtained earthworm antibacterial crude protein can inhibit Pseudomonas aeruginosa, Enterobacter cloacae, Proteus vulgaris and Serratia marcescens after being dissolved in sterile water. The application has the advantages of wide raw material sources, simple preparation method and the like, and has potential values in aspects of livestock breeding, medical treatment and health care and the like.

The invention discloses a biological prevention and control method for guava root-knot nematodes, and belongs to the technical field of biological prevention and control of diseases and insect pests, and the biological prevention and control method for guava root-knot nematodes comprises the following steps: adding a complex microbial inoculant into excrement, the method comprises the following steps: fermenting a mixture of pseudomonas fluorescens ACCC 03936, pseudomonas fluorescens ACCC 01144, pseudomonas aeruginosa ACCC 60044 and proteusbacillus vulgaris ACCC 11766 to obtain a biological fermentation solution, applying the biological fermentation solution twice in a young psidium guajave shoot germination period and a nematode infection peak period, and performing conventional field management after the biological fermentation solution is applied. The method can effectively prevent and treat guava root-knot nematode infection, is ecological and environment-friendly, is simple and convenient, and can obviously improve the yield and quality of guavas.

The invention belongs to the technical field of biological medicine, and discloses an auxiliary marker for diagnosing atherosclerotic plaque instability and acute coronary syndrome and application of the auxiliary marker. The auxiliary marker is selected from at least one of the following: a) proteus mirabilis; b) extracellular vesicles derived from proteus mirabilis; and c) HpmA in the extracellular vesicles. The auxiliary marker is used for preparing a product for diagnosing, screening or evaluating atherosclerotic plaque instability and / or acute coronary syndrome. It is proved that proteus mirabilis is remarkably enriched in ACS patients, and extracellular vesicles carrying HpmA penetrate through intestinal barriers and are enriched at atherosclerotic plaques. The vesicles inhibit FAK / SRC signal channels through HpmA, induce phenotypic transformation of VSMC and promote plaque instability, and an action target and a screening model are provided for drug development. Detection is carried out through non-invasive samples such as excrement or blood, and the method is easy to popularize.

The invention discloses an L-amino acid deaminase mutant and application thereof. The invention verifies that the L-amino acid deaminase derived from proteus haunhai has the capability of catalyzing L-glutamic acid to generate alpha-KG for the first time. Through protein three-dimensional structure simulation and the like, it is predicted that related sites possibly influencing catalysis and combination are I64, G257, Q278 and M440, site-saturated mutation is carried out, and a mutant and engineering bacteria for efficient catalytic synthesis of alpha-KG are obtained. Compared with a wild type, the catalytic activity of the mutant for catalyzing L-glutamic acid to generate alpha-ketoglutaric acid is remarkably improved, and the mutant has a wide prospect of large-scale industrial application.

This invention discloses a cholesterol-regulated bio-hybrid nanoparticle formulation, its preparation method, and its application, belonging to the field of biomedical technology. The preparation method includes: preparing a gold nanoparticle solution; mixing the gold nanoparticle solution with a photosynthetic bacteria culture to obtain a PSB@GNP complex; mixing the PSB@GNP complex with a Proteus mirabilis culture to obtain a PM-PSB@GNP core solution; and modifying the PM-PSB@GNP core solution with a coating solution followed by spray drying to obtain the bio-hybrid nanoparticle formulation EC-PM-PSB@GNP. The preparation process of this invention is simple and controllable, requiring no complex or precise equipment. Oral administration is convenient, resulting in high patient compliance. Compared to traditional chemical drugs and injectable formulations, it significantly reduces systemic toxicity and environmental pollution risks, while also reducing treatment procedures and medication costs, achieving efficient, safe, and precise colorectal cancer treatment and meeting clinical application needs.

A probiotic for inhibiting growth of Proteus mirabilis, including a microorganism selected from the group consisting of Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus reuteri, Bifidobacterium animalis subsp. lactis, Bifidobacterium infantis, Bifidobacterium bifidum and a combination thereof. A fermentation broth and an application of the probiotic are further provided.

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and / or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and / or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin and / or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and / or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and / or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

The invention provides clostridium butyricum pandaZhang, a microbial agent, a bacteriostatic agent and application of the clostridium butyricum pandaZhang, and belongs to the technical field of microorganisms. The preservation number of the clostridium butyricum pandaZhang is CCTCC (China Center for Type Culture Collection) NO: M 20253041. The clostridium butyricum pandaZhang is strong in antibacterial ability and wide in antibacterial spectrum, can generate antibacterial active substances such as lanheheptide through metabolism, and has a remarkable inhibition effect on various pathogenic bacteria such as escherichia coli, staphylococcus aureus, klebsiella pneumoniae, salmonella and proteus mirabilis. The strain has outstanding short-chain fatty acid production capacity, and can efficiently produce key metabolites such as propionic acid and butyric acid. When the strain is applied to breeding of weaned piglets, the growth performance of the piglets can be remarkably improved, the diarrhea rate of the weaned piglets is reduced, the intestinal health of the piglets is improved, and healthy and efficient breeding of the piglets under the antibiotic-free condition is achieved.

The invention belongs to the technical field of biology, and relates to a salmonella targeted antibacterial peptide Yisi-1 and application thereof. The amino acid sequence of the targeted antibacterial peptide Yisi-1 is alanine, isoleucine, lysine, glycine, valine, lysine, alanine, glycine, isoleucine, arginine, leucine, glycine, lysine, lysine, glycine, leucine, arginine and alanine, and the amino acid sequence of the targeted antibacterial peptide Yisi-1 is shown in the description. The molecular weight of the targeted antibacterial peptide Yisi-1 is 1836.3 Da, the isoelectric point of the targeted antibacterial peptide Yisi-1 is 12.1, and the targeted antibacterial peptide Yisi-1 has six positive charges, is high in amphipathy, has no bacteriostatic activity on staphylococcus aureus, escherichia coli, proteus mirabilis, pseudomonas aeruginosa, candida albicans and the like, only has bacteriostatic activity on salmonella, and has relatively low hemolytic activity on chicken erythrocytes. The targeted antibacterial peptide Yisi-1 disclosed by the invention is expected to become a novel antibiotic substitute and has a good application prospect in prevention, diagnosis, treatment and identification of salmonella and infection thereof.

The application discloses a fermentation feed feeding method for promoting growth of Ictalurus punctatus and improving intestinal flora. When cultivated, the Ictalurus punctatus is fed with puffed compound feed and fermentation feed; every other week, 20% of the puffed compound feed is replaced by the fermentation feed, and the mixed feed is fed for one week, and the feed is fed twice a day in the morning and in the evening. When cultivated by the method, the weight of the Ictalurus punctatus in the experimental group with the added fermentation feed is higher than that in the control group, and the weight of the Ictalurus punctatus in the interval feeding group is the highest and is significantly higher than that in the control group. Because the fermentation feed is continuously added, the diversity and richness of the intestinal flora of the Ictalurus punctatus decrease, especially the abundance of the actinobacteria and cyanobacteria, and the relative abundance of the opportunistic pathogen proteobacteria is increased, thereby affecting the growth of the Ictalurus punctatus.

The invention belongs to the technical field of microorganisms, and particularly relates to a new strain of microbacterium and application thereof. The bacterial strain is separated from rapana venosa, is a new species of Microbacterium sp. M-28, is registered and preserved in the China Center for Type Culture Collection (CCTCC), and has a preservation number of CCTCC NO: M 20241861. The invention also discloses a method for preparing the bacterial strain. The microbacterium sp. M-28 strain disclosed by the invention has obvious bacteriostatic activity on bacillus subtilis, shewanella, staphylococcus aureus and proteusbacillus vulgaris, has obvious acetylcholin esterase inhibitory activity, has obvious antioxidant activity, has alpha-glucosidase inhibitory activity, can generate casein enzyme and amylase, and can be used for preparing a food additive. The strain can be applied to preparation of a bacteriostatic agent, an acetylcholin esterase inhibitor, an antioxidant, an alpha-glucosidase inhibitor, casein and amylase, can also replace the bacteriostatic agent, the antioxidant, the casein and the amylase in a viable form to be applied to industrial production, and has a very good development and application prospect.

The present invention relates to a preparation method, a prepared slice and an application of Arisaema cum Bile, and belongs to the technical field of processing of prepared slices of traditional Chinese medicine. The preparation method comprises the following preparation steps: (1) pulverizing Pueraria lobata and / or Arisaema heterophyllum to obtain medicinal powder; (2) mixing bile and the medicinal powder in a mass ratio of 4-6:1, adding fermentation bacteria for fermentation to obtain a fermentation broth; (3) filling the fermentation broth into a bovine gallbladder and suspending it for fermentation to obtain a fermented product; (4) drying the fermented product at a low temperature and pulverizing it to obtain the Arisaema cum Bile prepared slice, wherein the fermentation bacteria are selected from at least one of Proteus mirabilis, Bacillus velezensis, Kazachstania servazzii and Penicillium. The prepared slice is prepared by using all of Pueraria lobata or adding Arisaema heterophyllum and fermenting with a mixed strain, and the content of active free cholic acid in the obtained fermented product is high, and it has preventive and therapeutic effects on various diseases.

The invention discloses a biological hybrid nano preparation based on cholesterol regulation and control as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method comprises the following steps: preparing a gold nanoparticle solution, mixing the gold nanoparticle solution with a photosynthetic bacterium solution to obtain a PSB-coated GNP complex, mixing the PSB-coated GNP complex with a proteus mirabilis bacterium solution to obtain a PM-PSB-coated GNP core solution, modifying the PM-PSB-coated GNP core solution with a coating solution, and carrying out spray drying to obtain the biological hybrid nano preparation EC-PM-PSB-coated GNP. The preparation process is simple and controllable, complex and precise equipment is not needed, the oral administration mode is convenient, the patient compliance is high, compared with traditional chemical drugs and injection preparations, the toxic and side effects of the whole body and the environmental pollution risk are greatly reduced, meanwhile, the treatment procedures and the medication cost are reduced, efficient, safe and precise colorectal cancer treatment is achieved, and the clinical application prospect is wide. The clinical application requirements are met.